Published in final edited form as:

Clin Genitourin Cancer. 2011 December ; 9(2): 130–132. doi:10.1016/j.clgc.2011.06.001.

Case Report: Responses to Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer after Extensive Docetaxel Treatment

Elizabeth A. Guancial, MD and

Clinical Fellow in Hematology and Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Smith 353, Boston, MA 02115, 617-632-3779 (telephone), 617-632-5822 (fax), eguancial@partners.org

Mary-Ellen Taplin, MD

Associate Professor of Medicine, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana 1232D, Boston, MA 02115, 617-632-3237 (telephone), 617-632-2165 (fax), mary_taplin@dfci.harvard.edu

Introduction

Cabazitaxel (Jevtana; sanofi-aventis) is a novel taxane that was approved by the U.S. Food and Drug Administration in June 2010, in combination with prednisone, for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (1). Approval of this agent was based on a randomized, open-label, phase III trial (TROPIC) of 755 men with mCRPC with progression of disease during or after treatment with docetaxel. Participants were randomized to cabazitaxel (25 mg/m² every three weeks) or mitoxantrone (12 mg/m² every three weeks), both in combination with prednisone 10 mg daily (2). The cabazitaxel-treated patients demonstrated statistically significant improvements in overall survival (15.1 versus 12.7 months) and progression-free survival (2.8 versus 1.4 months). We describe two patients with extensive mCRPC, heavily pretreated who experienced dramatic responses with PSA decline, improvement in tumor-related disseminated intravascular coagulation (DIC), and stabilization of visceral disease with cabazitaxel. These cases illustrate that meaningful responses with low toxicity can be achieved with cabazitaxel in aggressive mCRPC despite significant prior exposure to taxanes.

Case Report #1

In July 1995, a 49-year-old man presented with a PSA of 18.4 and Gleason 7 (3+4) prostate adenocarcinoma. He underwent a radical prostatectomy and had extensive perineural invasion and extracapsular extension of tumor. His post-operative PSA nadir was 4.0, and he received salvage external beam radiation with a PSA nadir of 1.0. He began androgen deprivation therapy (ADT) in February 1996, and over the next six years received multiple hormonal agents, including flutamide and bicalutamide, for PSA recurrence. In 2002, he received fowlpox vaccination combined with IL-2. He was treated with ketoconazole for asymptomatic bone metastases and PSA declined from 180 to 42 over six months. From 2004 through 2010, he received a total of five separate docetaxel-containing chemotherapy regimens for progression of bone-only metastatic disease accompanied by decreases in PSA with intermittent breaks for fatigue: single-agent docetaxel (4 cycles), docetaxel/carboplatin (12 cycles), mitoxantrone/prednisone (14 cycles), docetaxel/carboplatin (2 cycles), docetaxel/oxaliplatin (3 cycles), and navelbine (3 cycles).

By March 2009, PSA was 2,564, and he was started on a trial of a novel PI3 kinase/mTOR inhibitor. Following his first cycle of treatment, he developed a decrease in fibrinogen and platelets accompanied by a rise in PT, PTT and INR. He was diagnosed with DIC secondary

to progression of metastatic prostate cancer and taken off study. He resumed ketoconazole and remained stable for 14 months during which time his thrombocytopenia and coagulation studies improved. In June 2010, he began weekly docetaxel for recurrent cancer-related DIC with apparent bruising and gum bleeding. After a total of 12 treatments of weekly docetaxel, his fibrinogen and platelets were no longer responsive to treatment, PSA had risen to 7,258, and his performance status (PS) had declined 2.

In November 2010, he began cabazitaxel at 10 mg/m² every other week with improvement in his thrombocytopenia and fibrinogen and decline in PSA to 4,500 (see figure 1). By February 2011, he developed recurrent ecchymoses, and his platelets fell to 50,000 with a slight decline in fibrinogen and rise in PSA to 5,500. The cabazitaxel dose was increased to weekly (no growth factor support) with improvement in laboratory values. After 22 weeks, he had a hospital admission for syncope and he elected to stop cabazitaxel and treat with abiraterone. Adverse effects of cabazitaxel included stable anemia and leucopenia without fever or infections.

Case Report #2

In 1989, a 64-year-old man presented with prostate adenocarcinoma metastatic to pelvic lymph nodes. He was treated with radiation therapy and ADT. In 2002, after 13 years of ADT, he was found to have isolated biopsy-proven prostate cancer in his mediastinal lymph nodes. He began chemotherapy with docetaxel/estramustine. He experienced a complete radiographic and PSA response after three cycles. Subsequent to this first course of chemotherapy, he began ketoconazole for a rising PSA. In July of 2004, he presented with dyspnea and chest pain and had recurrent disease in the mediastinum with a soft tissue mass surrounding the left upper lobe bronchus. He received six cycles of docetaxel/estramustine with a PSA response followed by palliative radiation to the mediastinum. Between September 2007 and August 2010, he received four more courses of docetaxel [docetaxel/estramustine (3 cycles), single-agent docetaxel (7 cycles), and docetaxel/carboplatin (12 cycles)] for progression of mediastinal lymphadenopathy and the development of pulmonary lymphangitic carcinomatosis and liver metastases. Each course of chemotherapy resulted in PSA and radiographic responses however subsequent courses were associated with a smaller PSA decline and shorter time to relapse. He received a second course of palliative radiation to the mediastinum for left upper lobe collapse secondary to compressive adenopathy and radiation to skull and C1 vertebrae.

In November 2010, he presented with worsening PS, weight loss, progression of visceral disease, and PSA of 345. He began treatment with cabazitaxel 20 mg/m² every 3 weeks with pegfilgrastim; following his first cycle, he experienced a PSA flare to over 400 with subsequent decline to 200 (figure 2). He tolerated therapy well with improved PS and weight gain, despite mild fatigue and a slight anemia. He did not experience any fever or documented infections. He elected to stop cabazitaxel after 20 weeks of therapy following a hospital admission for dehydration, and he was treated with abiraterone.

Discussion

The average life expectancy for mCRPC ranges from 9 to 23 months (3). DIC with subsequent end-organ failure secondary to thrombus formation in small blood vessels is a recognized complication of mCRPC (4), though debate exists over the actual incidence (5). As with other etiologies of DIC, hematologic abnormalities resolve following successful treatment of the underlying condition, and reports document improvements in DIC in mCRPC with multiple forms of hormonal manipulation (6)(7)(8). Chemotherapy with docetaxel has also been reported to reverse mCRPC related DIC (9, 10).

The TAX 327 trial established docetaxel with prednisone as the standard of care for men with chemotherapy-naïve mCRPC (11). After a median duration of follow-up of 21 months, patients treated with docetaxel (75 mg/m² every three weeks), had a median survival of 18.9 months compared to 16.5 and 17.4 months for the groups treated with mitoxantrone or weekly docetaxel, respectively. These survival differences persisted after three and a half years of follow-up (12, 13). However, the majority of patients with mCRPC progress within nine months of first-line chemotherapy (11, 14, 15), and less than 50% receive any form of second-line therapy despite a good PS and the desire for additional treatment (16). Cabazitaxel is the first FDA approved agent for second-line chemotherapy in mCRPR following treatment with docetaxel.

As illustrated by the two cases presented, some patients with advanced disease, including DIC, visceral metastases, and extremely elevated PSA, will continue to respond to docetaxel well into their fifth and sixth courses of treatment with this agent. These patients demonstrate that neither significant prior docetaxel, nor aggressive, advanced disease preclude treatment responses to the cabazitaxel. This is supported by preclinical data which confirmed activity of cabazitaxel in cell lines resistant to docetaxel (17, 18). Review of the baseline characteristics and treatment histories of patients in the TROPIC study further highlights how the two patients described here represent extremes in clinical presentation and heavy prior treatment. The median serum PSA concentration of patients in TROPIC who received cabazitaxel was 143.9 (2), in contrast to 7,258 and 403 in patient #1 and patient #2 respectively. Eighty four percent of patients treated with cabazitaxel in TROPIC had received a single previous docetaxel-based regimen, and only two percent had received two regimens for a median total previous docetaxel dose of 576.6 mg/m². Patient #1 received a cumulative dose of docetaxel in excess of 3,800 mg/m²; patient #2 received a cumulative dose in excess of 5,400 mg/m². It is our clinical impression that the two patients reported here received improved quality of life and a survival benefit from cabazitaxel.

The recommended dose of cabazitaxel based on phase I studies was 25 mg/m² administered as a one hour infusion every three weeks (19, 20). Weekly doses up to 12 mg/m² were also evaluated in phase I and considered safe. The most common toxicities observed with cabazitaxel in the TROPIC trial were anemia (97%) and neutropenia (94%), febrile neutropenia (8%), and there were 7 deaths related to neutropenia and infection. Given this toxicity profile, we prescribed cabazitaxel with caution in our patients choosing 10 mg/m² every other week initially (increasing to 10 mg/m² weekly) in patient #1 and 20 mg/m² with pegfilgrastim in patient 2. Both patients received clinical and radiographic benefit from cabazitaxel for 20-22 weeks and both had an ECOG PS of 1 at the time cabazitaxel was stopped and abiraterone was started.

Conclusions

Second-line chemotherapy options for mCRPC were an unmet need in oncology until the recent approval of cabazitaxel. Even with significant prior treatment with docetaxel, responses to cabazitaxel are seen in the setting of aggressive, advanced mCRPC, and cabazitaxel can be administered safely in heavily pretreated patients. As experience with cabazitaxel grows, it will be important to identify patients and diseasespecific factors predictive of response to cabazitaxel in order to treat patients who are most likely to benefit.

References

1. FDA labeling information - jevtana (cabazitaxel). [Internet]. FDA website. 2010. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201023lbl.pdf

2. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. *Lancet*. 2010 Oct 2; 376(9747):1147–1154. [PubMed: 20888992]
3. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. *J Clin Oncol*. 2003 Apr 1; 21(7):1232–1237. [PubMed: 12663709]
4. de la Fouchardiere C, Flechon A, Droz JP. Coagulopathy in prostate cancer. *Neth J Med*. 2003 Nov; 61(11):347–354. [PubMed: 14768717]
5. Oh, WK. Hematologic complications of prostate cancer. In: Kantoff, PW.; Carroll, PR.; D'Amico, AV.; Ross, RK.; Isaacs, JT.; Scher, HL., editors. *Prostate Cancer Principles and Practice*. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 602
6. Duran I, Tannock IF. Disseminated intravascular coagulation as the presenting sign of metastatic prostate cancer. *J Gen Intern Med*. 2006 Nov; 21(11):C6–C8. [PubMed: 17026724]
7. Lowe FC, Somers WJ. The use of ketoconazole in the emergency management of disseminated intravascular coagulation due to metastatic prostatic cancer. *J Urol*. 1987 May; 137(5):1000–1002. [PubMed: 3573156]
8. Litt MR, Bell WR, Lepor HA. Disseminated intravascular coagulation in carcinoma of the prostate: Role of estrogen therapy. *JAMA*. 1987; 258:1361–1362. [PubMed: 3625935]
9. Sallah S, Gagnon GA. Reversion of primary hyperfibrinogenolysis in patients with hormone-refractory prostate cancer using docetaxel. *Cancer Invest*. 2000; 18(3):191–196. [PubMed: 10754987]
10. Cooper DL, Sandler AB, Wilson LD, Duffy TP. Disseminated intravascular coagulation and excessive fibrinolysis in a patient with metastatic prostate cancer response to epsilon-aminocaproic acid. *Cancer*. 1992 Aug 1; 70(3):656–658. [PubMed: 1623480]
11. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *N Engl J Med*. 2004 Oct 7; 351(15):1502–1512. [PubMed: 15470213]
12. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. *J Clin Oncol*. 2008 Jan 10; 26(2):242–245. [PubMed: 18182665]
13. Basch EM, Somerfield MR, Beer TM, Carducci MA, Higano CS, Hussain MH, et al. American society of clinical oncology endorsement of the cancer care ontario practice guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. *J Clin Oncol*. 2007 Nov 20; 25(33):5313–5318. [PubMed: 17925542]
14. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. *N Engl J Med*. 2004 Oct 7; 351(15):1513–1520. [PubMed: 15470214]
15. Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. *J Clin Oncol*. 2005 May 20; 23(15):3343–3351. [PubMed: 15738542]
16. Garmey EG, Sartor O, Halabi S, Vogelzang NJ. Second-line chemotherapy for advanced hormone-refractory prostate cancer. *Clin Adv Hematol Oncol*. 2008 Feb; 6(2):118, 22, 127–132. [PubMed: 18347563]
17. Bissery MC, Bouchard H, Riou JF, et al. Preclinical evaluation of TXD258, a new taxoid. *Proc Am Assoc Cancer Res*. 2000; 41:214. (abs 1364).
18. Aller AW, Kraus LA, Bissery MC. In vitro activity of TXD258 in chemotherapeutic resistant tumor cell lines. *Proc Am Assoc Cancer Res*. 2000; 41:303. (abst 1923).
19. Mita AC, Denis LJ, Rowinsky EK, Debono JS, Goetz AD, Ochoa L, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. *Clin Cancer Res*. 2009 Jan 15; 15(2):723–730. [PubMed: 19147780]

20. Pivot X, Koralewski P, Hidalgo JL, Chan A, Goncalves A, Schwartzmann G, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. *Ann Oncol.* 2008 Sep; 19(9):1547–1552. [PubMed: 18436520]

Clinical Practice Points

- Cabazitaxel is the first FDA approved agent for second-line chemotherapy in mCRPR following treatment with docetaxel.
- Cabazitaxel can safely be administered to patients with mCRPC, including those with advanced visceral disease and tumor-related DIC, who are heavily pretreated with docetaxel-containing chemotherapy regimens.
- Treatment with cabazitaxel can reverse mCRPC-related DIC and produce objective PSA responses and stabilization of visceral disease.

Figure 1.
Hematologic and PSA tumor marker response to cabazitaxel treatment for patient #1.

Figure 2.
PSA tumor marker response to cabazitaxel treatment for patient #2.